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Abstract
Background: Analysis of the viral genome for drug resistance mutations is state-of-the-art for guiding treatment selection
for human immunodeficiency virus type 1 (HIV-1)-infected patients. These mutations alter the structure of viral target
proteins and reduce or in the worst case completely inhibit the effect of antiretroviral compounds while maintaining the
ability for effective replication. Modern anti-HIV-1 regimens comprise multiple drugs in order to prevent or at least delay the
development of resistance mutations. However, commonly used HIV-1 genotype interpretation systems provide only
classifications for single drugs. The EuResist initiative has collected data from about 18,500 patients to train three classifiers
for predicting response to combination antiretroviral therapy, given the viral genotype and further information. In this work
we compare different classifier fusion methods for combining the individual classifiers.
Principal Findings: The individual classifiers yielded similar performance, and all the combination approaches considered
performed equally well. The gain in performance due to combining methods did not reach statistical significance compared
to the single best individual classifier on the complete training set. However, on smaller training set sizes (200 to 1,600
instances compared to 2,700) the combination significantly outperformed the individual classifiers (p,0.01; paired one-
sided Wilcoxon test). Together with a consistent reduction of the standard deviation compared to the individual prediction
engines this shows a more robust behavior of the combined system. Moreover, using the combined system we were able to
identify a class of therapy courses that led to a consistent underestimation (about 0.05 AUC) of the system performance.
Discovery of these therapy courses is a further hint for the robustness of the combined system.
Conclusion: The combined EuResist prediction engine is freely available at http://engine.euresist.org.
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Introduction
To date 33.2 million [30.6–36.1 million] (http://www.who.int/
mediacentre/news/releases/2007/pr61/en/index.html) people are
estimated to be infected with the human immunodeficiency virus
type 1 (HIV-1). Currently, about 20 antiretroviral compounds
targeting four different stages of the viral replication cycle exist to
fight the pandemic. Targets of these antiretrovirals are: entry of the
virus into the host cell, reverse transcription of the viral RNA into
DNA, integration of the viral genome into the host genome, and
maturation of new viral particles through proteolytic processing of
viral polyproteins. The group of drugs available for the longest time
interrupt the process of reverse transcription. These reverse
transcriptase (RT) inhibitors are subdivided in two groups.
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
are chemically modified versions of deoxynucleosides that interfere
with reverse transcription by blocking chain elongation after their
incorporation into newly synthesized DNA.Instead, non-nucleoside
reverse transcriptase inhibitors (NNRTIs) bind to the viral reverse
transcriptase and block DNA polymerization by impairing the
mobility of particular RT domains. Protease inhibitors (PIs) target
the assembly of new infectious particles by occupying the active site
of the viral protease that processes viral precursor polyproteins into
structurally and functionally mature proteins. Compounds for
preventing entry of the virus into the host cell and integration of the
viral genome in the host’s genome are relatively new, and not yet
established or infrequently used in clinical routine.
Antiretroviral therapy
The large variety of compounds designed for combating a single
pathogen is the response to the virus’ potential of escaping drug
pressure by developing resistance mutations that reduce the
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resistance are generated frequently, since the process of reverse
transcription lacks a proofreading mechanism and generates single
nucleotide mutations at a high rate (3.4 * 10
25 per nucleotide base
per cycle of replication; [1]). To date, NRTIs, NNRTIs and PIs
form the basis for daily routine in treating HIV patients. The
current standard of care, highly active antiretroviral therapy
(HAART), aims at maximally suppressing the viral replication
and thus preventing or at least delaying the development of resistant
variants and, thereby, the progression of the disease to AIDS and
death. A typical HAART comprises three or more drugs from at
least two different drug classes. Applying such a therapy can slow
down the emergence of resistant variants substantially, since
mutants that are resistant to all components of the regimen are
unlikely to preexist, and new variants need to bring forth several
escape mutations while retaining the ability of effective replication.
However, treatment failure is eventually observed in most of the
patients. When it occurs, clinicians face the problem of finding a
new effective drug cocktail. Despite the presence of more than 20
different compounds this is a challenge, since the number of
treatment options in patients failing HAART is not only reduced by
resistance to the drugs administered, but also by resistance to
compounds never given to the patient. This is due to the
phenomenon of cross-resistance, by which a virus by becoming
resistant to a drug simultaneously acquires resistance to most if not
all drugs in the same drug class. Selecting an effective therapy is
mandatory, because ineffective drugs lower the barrier for the virus
to escape the remaining compounds and tend to result in a
treatment failure after a short period.
Genotypic assays are now standard methods for guiding
treatment selection by providing the genetic information of the
viral strain prevalent in the patient. The information routinely
extracted from the viral genome comprises all the 99 amino acid
positions of the protease and the first 240 amino acid positions of
the RT. Several existing tools (reviewed in [2]) support the
interpretation of the complex dependence between the viral
genotype and its drug susceptibility profile in vitro and in vivo.
Furthermore, a reference list of resistance mutations is maintained
by the International AIDS Society (IAS) [3]. Despite the
availability of tools for interpreting viral resistance against single
drugs there are no guidelines on how this information has to be
used to rate clinical practice regimens comprising multiple
compounds. Furthermore, none of the currently used genotype
interpretation systems addresses the critical issue of evolution of
the present virus to resistance to other drug regimens.
The EuResist approach
The EuResist project (IST-2004-027173) aims at integrating
clinical and virological data from a large number of patients and
training a data-driven therapy response prediction for drug
combinations rather than for single drugs. The EuResist Integrated
Database (EIDB) currently comprises data from Italy (ARCA
database;http://www.hivarca.net/),Germany(AREVIRdatabase;
[4]), Sweden (Karolinska Infectious Diseases and Clinical Virology
Department), and Luxembourg (Retrovirology Laboratory, CRP-
Sante ´). In order to train a classifier, response to antiretroviral
therapy is dichotomized. A therapy success is defined according to
clinical standards as a viral load (VL; copies of viral RNA per
milliliter of blood) measure below 500 copies per milliliter or a
reduction of 2 log compared to the baseline VL measure. Thus, a
viral genotype and a baseline VL measure must exist at maximum
three months before start of the therapy and a follow-up VL
measure must be available after 8 (4–12) weeks of treatment to allow
for inclusion of that therapy into the training data. Statistics of the
EIDB and available training data are shown in Table 1. Three
classification models for predicting response to combination
antiretroviral therapy on the basis of the viral genotype and other
clinical features were independently developed. The single
approaches are described below. The final EuResist prediction
system provides a ranking of a number of combination therapies
with respect to their probability of success, given the viral genotype
and additional clinical information. Basis for the ranking are the
predictions of the individual classifiers. In order to provide a more
reliable and robust recommendation several methods for combining
the individual classifiers were investigated.
Related work
Lathrop and Pazzani [5] formulated the optimization of an anti-
HIV-1 regimen with respect to drug resistance given a set of HIV-
1 sequences as a triply nested combinatorial optimization problem.
They presented a branch-and-bound algorithm to efficiently solve
this problem. In [6] committees of Artificial Neural Networks were
used to predict virological response to antiretroviral treatment.
The response was not dichotomized but the actual change
between baseline and follow-up VL measure was predicted. Apart
from the viral genotype other clinical features were considered to
enhance performance. The approach was trained and validated on
a rather small set of treatment change episodes (1,150 for training,
100 for testing). In [7] the online tool geno2pheno-THEO was
introduced which uses exclusively features derived from the viral
genome and a quantitative notion of the probability of the virus
escaping to resistance in the future, namely the genetic barrier to
drug resistance, to predict success of an intended regimen. The
response to antiretroviral therapy was dichotomized as well,
although using a different definition leading to a set of 6,300
genotype-treatment pairs. However, none of the aforementioned
approaches tried to combine multiple highly optimized classifiers
for achieving a more accurate and robust prediction.
Table 1. Summary of the EuResist Integrated Database (release 11/2007) and training and test set.
Patients Sequences VL measurements Therapies Successes Failures
EIDB 18,467 22,006 240,795 64,864 - -
Labeled Therapies 8,223 3,492 40,498 20,249 13,935 6,314
Training Set 2,389 2,722 5,444 2,722 1,822 900
Test Set 297 301 602 301 202 99
The table displays the number of Patients, Sequences, VL measurements, and Therapies for the complete EuResist Integrated Database (EIDB) and the set of therapies
that could be labeled with the definition. 469 of the sequences associated with all labeled therapies belong to historic genotypes and are not directly associated with a
therapy change. Moreover, detailed information on training set and test set (comprising labeled therapies with an associated sequence) is given.
doi:10.1371/journal.pone.0003470.t001
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literature (e.g. [8]), and is also an inherent part of novel classification
methods like bagging and boosting. Previously, Sinisi et al. applied
multiple regression methods for predicting HIV-1 in vitro drug
resistance to one protease inhibitor [9]. Typically, different
combination approaches are compared on multiple datasets to
identify the most suitable method for many applications. However,
the presented comparison aims specifically at finding the best
combinationmethod for prediction response to anti HIV-1 therapy.
Furthermore,we presenta detailed analysisinterms ofperformance
and robustness of the complete EuResist prediction system
previously introduced in [10]. Similarities to that publication are
a mere necessity for ensuring autonomy of this work.
Methods
Individual classifiers
Three classifiers for inferring virological response to anti HIV-1
therapy were developed. One constraint on the classifiers was that
they receive the viral genotype and the intended treatment as the only
information, since the viral genotype is the information to which all
users interested in using a decision support system must have access.
However, in many cases additional information is available to the
user, such as the VL, the CD4+ cell count, information on previous
treatment lines and previously obtained viral genotypes, the patient’s
age, or the patient’s risk group. In the remainder of this paper we will
refer to features derived from the minimal and full set of information
as minimal feature set and maximal feature set, respectively. Features
that can be derived from the minimal (maximal) feature set during
prediction were allowed for usage in the minimal (maximal) feature
set as well. For each of the three systems a different feature selection
method was applied. Although various statistical learning approaches
were explored for the systems, logistic regression proved to be the
most accurate method in all cases. Details on the individual engines
are given in the following subsections.
Generative Discriminative engine. The Generative
Discriminative (GD) engine applies generative models to derive
additional features for the classification using logistic regression.
Only a small percentage of therapies in the database (Table 1)
have an associated genotype and are therefore suitable for training
a classifier that is supposed to receive sequence information.
However, a much larger fraction of the therapies can be labeled as
success or failure on the basis of the baseline and follow-up VL
measures alone, since for the labeling no viral genotype is
required. The GD engine thus trains a Bayesian network on about
20,000 therapies (with and without associated genotype). The
network is organized in three layers and uses an indicator for the
outcome of the therapy, indicators for single drugs, and indicators
for drug classes. This generative model is used to compute a
probability of therapy success on the basis of the drug combination
alone. This probability is used as an additional feature for the
classification by logistic regression, the discriminative step of the
approach. Furthermore, indicators for single drugs and single
mutations are input for the logistic regression.
Indicators representing a drug class are replaced with a count of
the number of previously used drugs from that class when working
with the maximal feature set. In this way information about past
treatments is incorporated. In addition to features from the minimal
set, the maximal feature set comprises indicators for mutations in
previously observed genotypes, the number of past treatment lines,
and the VL measure at baseline. Correlation between single
mutations and the outcome of the therapy was used to select
relevant mutations for the model. A detailed description on the
network’s setup and the selected mutations can be found in [10].
Mixed Effects engine. The Mixed Effects (ME) engine
explores the benefit of including second- and third-order variable
interactions. Since modern regimens combine multiple drugs,
binary indicators representing usage of two or three specific
drugs in the same regimen are introduced. Further indicators
represent the occurrence of two specific mutations in the viral
genome for modeling interaction effects between them.
Moreover, interactions between specific single drugs and single
mutations or pairs of drugs and single mutations are represented
by additional covariates. In addition to the terms modeling the
mixed effects other clinical measures, demographic information,
and covariates based on previous treatments are used (further
information in [10]).
The large number of features (due to the mixed effects) requires
a strong effort in feature selection. Thus, multiple feature selection
methods were used for generating candidate feature sets. Filters
and embedded methods, i.e. methods that are intrinsically tied to a
statistical learning method, were applied sequentially: (i) univari-
able filters, such as x
2 with rank-sum test and correlation-based
feature selection [11] , were applied to reduce the set of candidate
features; (ii) embedded multivariable methods, such as ridge
shrinkage [12] and Akaike information criterion (AIC) selection
[13] were used to eliminate correlated features and to assess the
significance of features with respect to the outcome in multivariate
analysis. In multiple 10-fold cross validation runs on the training
data the performance of the resulting feature sets were compared
with a t-statistic (adjusted for sample overlap and multiple testing).
The approach leading to the best feature set was applied on all
training samples to generate the final model. Unlike the GD
engine, the ME engine is based on one set of features only. Missing
variables are replaced by the mean (or mode) of that variable in
the training data.
Evolutionary engine. As stated before, one major obstacle in
HIV-1 treatment is the development of resistance mutations. The
Evolutionary (EV) engine uses derived evolutionary features to
model the virus’s expected escape path from drug therapy. The
representation of viral evolution is based on mutagenetic trees.
Briefly, a mutagenetic tree is reconstructed from all pairwise
probabilities of defined events. Here, these events are occurrences
of drug resistance mutations in the viral genome. Hence, a mixture
of reconstructed mutagenetic trees represents possible evolutionary
pathways towards drug resistance along with probabilities for the
development of the involved mutations [14]. Using
geno2pheno[resistance] [15], mutation patterns leading to
complete drug resistance against a single compound can be
identified. Together with the current drug resistance pattern of the
virus and the probabilities of the mutagenetic trees, the likelihood
of the virus remaining susceptible to that drug can be computed.
This likelihood is termed the genetic barrier to drug resistance
[16]. The genetic barrier to drug resistance is provided together
with other features, like indicators for single drugs in the treatment
and indicators for IAS mutations in the genotype. In the maximal
feature set, indicators for previous use of a drug and the baseline
VL measure extend this list. Interactions up to second order
between indicator variables are considered as well.
The feature selection approach is based on Support Vector
Machines (SVMs) with a linear kernel. The approach works in
three steps: (i) optimization of the cost parameter in a 10-fold
cross validation setting to maximize the area under the ROC
curve (AUC); (ii) generation of 25 different SVMs by 5
repetitions of 5-fold cross validation using the optimized cost
parameter; (iii) computation of the z-score for every feature. All
features with a mean z-score larger than 2 were selected for the
final model.
Inferring HIV Therapy Response
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In principle there are two approaches to combining classifiers,
namely classifier fusion and classifier selection. In classifier fusion
complete information on the feature space is provided to every
individual system and all outputs from the systems have to be
combined, whereas in classifier selection every system is an expert
in a specific domain of the feature space and the local expert alone
decides for the output of the ensemble. However, the individual
classifiers described above were designed to be global experts, thus
only classifier fusion methods were explored.
Methods for classifier fusion can operate on class labels or
continuous values (e.g. support, posterior probability) provided by
every classifier. The methods range from simple non-trainable
combiners like the majority vote, to very sophisticated methods
that require an additional training step. In order to find the best
combination method we compared several approaches ranging
from simple methods to more sophisticated ones. All results were
compared to a combination that has access to an oracle telling
which classifier is correct. Intuitively, the predictive performance
of this oracle represents the upper bound on the performance that
can be achieved by combining the classifiers. The following
subsections briefly introduce the combination methods considered.
Non-trainable combiners. As mentioned above, there are a
number of simple methods to combine outputs from multiple
classifiers. The most intuitive one is a simple majority vote, whereby
every individual classifier computes a class label (in this case
success or failure) and the label that receives the most votes is the
output of the ensemble. One can also combine the posterior
probability of observing a successful treatment as computed by the
logistic regression. This continuous measure can be combined
using further simple functions: mean returns the mean probability
of success by the three classifiers [17]; min yields the minimal
probability of success (a pessimistic measure); max results in the
maximal predicted probability of success (an optimistic measure);
median returns the median probability.
Meta-classifiers. The use of meta-classifiers is a more
sophisticated method of classifier combination, which uses the
individual classifiers’ outputs as input for a second classification
step. This allows for weighting the output of the individual
classifiers. In this work we applied quadratic discriminant analysis
(QDA), logistic regression, decision trees, and naı ¨ve Bayes (operating on
class labels) as meta-classifiers.
Decision templates and Dempster-Shafer. The decision
template combiner was introduced by Kuncheva [18]. The main
idea is to remember the most typical output of the individual
classifiers for each class, termed decision template. Given the
predictions for a new instance by all classifiers the class with the
closest (according to some distance measure) decision template is
the output of the ensemble.
Let x be an instance, then DPx is the associated decision profile.
The decision profile for an instance contains the support (e.g. the
posterior probability) by every classifier for every class. Thus, DPx
is an I6J-matrix, where I and J correspond to the number of
classifiers and classes, respectively. The decision template
combiner is trained by computing the decision templates DT for
every class. The DT for the class vj is simply the mean of all
decision profiles for instances x belonging that class. Hence,
DTj~
1
Nj
X
x[vj
DPx,Vj[ 1,...,J fg
where Nj is the number of elements in vj . For a new sample, the
corresponding decision profile is computed and compared to the
decision templates for all classes using a suitable distance measure.
The class with the closest decision template is the output of the
ensemble. Thus, the decision template combiner is a nearest-mean
classifier that operates on decision space rather than on feature
space. We used the squared Euclidean distance to compute the
support for every class:
mj x ðÞ ~1{
1
J1I
X J
j’~1
X I
i~1
DTj j’,i ðÞ {DPx j’,i ðÞ
   2
where DTj (j9,i )is the (j9,i ) th entry in DTj . Decision templates
were reported to outperform other combiners (e.g. [18] and [19]).
Decision templates can also be used to compute a combination
that is motivated by the evidence combination of the Dempster-
Shafer theory. Instead of computing the similarity between a
decision template and the decision profile, a more complex
computation is carried out as described in detail in [20]. We refer
to these two methods as Decision Templates and Dempster-Shafer,
respectively.
Clusters in decision space. Regions in decision space where
the classifiers disagree on the outcome are of particular interest in
classifier combination. Therefore, we propose the following
method that finds clusters in decision space and learns separate
logistic regression models for every cluster for fusing the individual
predictions. Let si be the posterior probability of observing a
successful treatment predicted by classifier i. Then we express the
(dis)agreement between two classifiers by computing:
aij~
0 classifiers i and j agree on the label
si{sj else
 
for all i and j where i,j . Thus, in case of disagreement between
two classifiers, the computed value expresses the magnitude of
disagreement. These agreements are computed for all instances of
the training set and used as input to a k-medoid clustering. For all
resulting k clusters an individual logistic regression is trained on all
instances associated with the cluster using the si as input. The idea
is that in clusters where e.g. classifier 1 and 2 agree, and classifier 3
tends to predict lower success probabilities the logistic regression
can either increase or decrease the influence of classifier 3,
depending on how often predictions by that classifier are correct or
incorrect, respectively.
When a new instance has to be classified then first the
agreement between the classifiers is computed for locating the
closest cluster. In a second step the logistic regression associated
with that cluster is used to calculate the output of the ensemble.
The number of clusters k, the only parameter of this method, is
optimized in a 10-fold cross validation. The approach is motivated
by the behavior knowledge space (BKS) method [21], which uses a look-
up table to generate the output of the ensemble. However, the
BKS method is known to easily over train, and does not work with
continuous predictions.
Local accuracy-based weighting. Woods et al. [22]
propose a method that uses one k-nearest-neighbor (knn)
classifier for every individual classifier to assess the local
accuracy of that classifier given the input features. The output is
solely given by the most reliable classifier of the ensemble. Since
the three classifiers in this setting are trained to be global experts,
we applied the proposed method to compute the reliability
estimate for each classifier given the features of an instance. In
contrast to the method proposed by Woods et al. [22], the output
is a weighted mean based on these reliability estimates.
Inferring HIV Therapy Response
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from the original instances are replaced by an indicator of whether
the classifier in question was correct on that instance or not. With
the replaced labels and the originally used features the knn
classifier reports the fraction of correctly classified samples in the
neighborhood of the query instance. This fraction can be used as a
local reliability estimator. The output by the ensemble is then
defined by a weighted mean:
  s s~
P
i risi P
i ri
where si and ri are the posterior probability of observing a
successful treatment and the local accuracy for classifier i,
respectively. For simplicity, only Euclidean distance was used in
the knn classifier, the number of neighbors k was optimized in a
10-fold cross validation setting.
Combining classifiers on the feature level. As described
above, every individual classifier uses a different feature set,
specifically, different derived features, but the same statistical
learning method. Thus, a further combination strategy is the use of
all features selected for the individual classifier as input to a single
logistic regression rather than computing a consensus of the
individual classifiers’ predictions.
Data
About 3,000 instances in the EIDB met the requirements for use
as a learning instance. From this complete set, 10% of the data
were randomly set aside and used as an independent test set
(Table 1). The split of the training data in 10 equally sized folds
was fixed, allowing for 10-fold cross validation of the individual
classifiers. The same 10 folds were used for a 10-fold cross
validation of the combination approaches. Classification perfor-
mance was measured as accuracy (i.e. the fraction of correctly
classified examples) and the area under the receiver operating
characteristics curve (AUC). Briefly, the AUC is a value between 0
and 1 and corresponds to the probability that a randomly selected
positive example receives a higher score than a randomly selected
negative example [23]. Thus, a higher AUC corresponds to a
better performance.
Results
Results for the individual classifiers using the minimal and
maximal feature set are summarized in Table 2. The use of the
extended feature set significantly improved the performance of the
GD and EV engine with respect to the AUC (p=0.001953 for
both) using a paired Wilcoxon test. With respect to accuracy only
the improvement observed by the EV engine reached statistical
significance (p=0.006836). Remarkably, replacement of all
missing additional features in the case of the ME engine when
working with the minimal feature set did not result in a significant
loss in performance (p=0.3125 and p=0.3120 with respect to
AUC and accuracy, respectively).
Correlation among classifiers
The performances of the individual classifiers were very similar.
Pearson’s correlation coefficient (r) indicated that the predicted
probability of success for the training instances using the minimal
(maximal) feature set were highly correlated (i.e. close to 1): GD-ME
0.812 (0.868); GD-EV 0.797 (0.786); ME-EV 0.774 (0.768). In fact,
the three classifiers agreed on the same label in 80.4% (81.7%) of the
cases using the minimal (maximal) feature set. Notably, agreement of
the three classifiers on the wrong label occurred more frequently in
instances labeled as failure than in instances labeled as success (39%
vs. 4% and 37% vs. 4% using the minimal and maximal feature set,
respectively; both p,2.2 * 10
216 with Fisher’s exact test).
This behavior led to further investigation of the instances
labeled as failure in the EIDB. Indeed, 145 of 350 failing instances,
which were predicted to be a success by all three engines, achieve a
VL below 500 copies per ml once during the course of the therapy.
However, this reduction was not achieved during the time interval
that was used in the applied definition of therapy success. Among
the remaining 550 failing cases this ocurred only 100 times. Using
a Fisher’s exact test this difference was highly significant
(p=4.8*10
214). These results were qualitatively the same when
using the maximal feature set.
Results of combination methods
Table 3 summarizes the results achieved by combining the
individual classifiers, and Figure 1 depicts the improvement in AUC
ontrainingand testsetofthecombinationmethodscomparedtothe
single best and single worst classifier, respectively. Most combina-
tion methods improved performance significantly over the single
worst classifier. However, only the oracle could establish a
significant improvement over the single best classifier. Overall,
performances of the combination approaches were quite similar.
The pessimistic min combiner yielded better performance than the
optimistic max combiner. Among the non-trainable approaches
tested, the mean combiner yielded the best performance. The logistic
regression was the best performing meta-classifier. In fact, the
logistic regression can be regarded as a weighted mean, with the
weights depending on the individual classifier’s accuracy, and the
correlation between classifiers. Moreover, using all features of the
individual classifiers as input to a single logistic regression did not
improve over the single best approach.
Table 2. Results for the individual classifiers on training set and test set.
Engine minimal feature set maximal feature set
AUC Accuracy AUC Accuracy
Train Test Train Test Train Test Train Test
GD 0.747 (0.027) 0.744 0.745 (0.024) 0.724 0.768 (0.025) 0.760 0.752 (0.028) 0.757
ME 0.758 (0.019) 0.745 0.748 (0.031) 0.757 0.762 (0.021) 0.742 0.754 (0.030) 0.757
EV 0.766 (0.030) 0.768 0.754 (0.031) 0.748 0.789 (0.023) 0.804 0.780 (0.032) 0.751
The table displays the performance, measured in AUC and Accuracy, achieved by the individual classifiers on the training set (using 10-fold cross validation; standard
deviation in brackets) and the test set using different feature sets.
doi:10.1371/journal.pone.0003470.t002
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classifiers, the mean combiner, and the combiner on the feature
level. The curves depict the mean AUC (after 10 repetitions) on the
test set achieved with varying sizes of the training set (25, 50, 100,
200, 400, 800, 1600, 2722). In every repetition the training samples
were randomly selected from the complete set of training instances.
The mean combiner appeared to learn faster and significantly
outperformed the single best engine with a training set size of 200
samples (p=0.009766 with a paired one-sided Wilcoxon test). The
improvement remained significant up to a training set size of 1,600
samples (p=0.001953). The combination on feature level was
significantly (p=0.001953) worse than the worst single approach for
all training set sizes (except for complete set).
Impact of ambiguous failures
In order to further study the impact of ambiguous failures (i.e.
instances labeled as failure but achieving a VL below 500 cp per
ml once during the course of treatment) on the performance of the
individual classifiers and the combination by mean or on the
feature level, they were removed from the training set, the test set,
or both sets. After removal the classifiers were retrained and tested
on the resulting new training and test set, respectively. The results
in Table 4 suggest that training with the ambiguous failures does not
impact the classification performance (columns ‘‘none’’ vs. ‘‘only
train’’, and columns ‘‘only test’’ vs. ‘‘both’’). However, the
ambiguous cases have great impact on the assessed performance.
Removal of these cases increases the resulting AUC by 0.05.
However, there might still be an influence of these ambiguous
failures on the performance of the trainable combination methods.
For verification we removed these cases whenever performance
measures were computed (also in 10-fold cross validation) and
trained a selection of the combination methods on the complete
training data and on the cleaned training data. The results in
Table 5 suggest that the trainable combination methods were not
biased by the ambiguous failures.
A possibility for circumventing the (artificial) dichotomization of
virological response is the prediction of change in VL between the
baseline value and the measurement taken at the follow-up time
point. Logistic regression was replaced by linear regression in the
individual classifiers for predicting the change in VL. Using the
maximalfeature setthe GD (ME, EV) engine achieveda correlation
(r) of 0.65860.023 (0.66460.023, 0.67960.020) on the training set
[10]. The mean combiner yielded a correlation of 0.69160.019.
However, the oracle achieved r=0.83460.012. Although small, the
difference between EV and the mean prediction reached statistical
significance (p=0.004883) using a one-sided paired Wilcoxon test.
Results on the test set were qualitatively the same: GD (ME, EV)
reached a correlation of 0.657 (0.642, 0.678) and the mean
combiner (oracle) reached 0.681 (0.814).
Discussion
The performance of the methods considered for combining the
individual classifiers improved only little over the single best
method on both sets of available features. It turns out that the
simple non-trainable methods perform quite well, especially the
mean combiner. This phenomenon has been previously discussed
in literature (e.g. [18] and [24]). Here we focused on finding the
best combination strategy for a particular task. The advantage of
the mean combiner is that it does not require an additional
training step (and therefore no additional data), although it ranges
among the best methods studied. Moreover, this combination
strategy is easy to explain to end-users of the prediction system.
Table 3. Results for the combined classifiers on training and test set.
Method minimal feature set maximal feature set
AUC Accuracy AUC Accuracy
Train Test Train Test Train Test Train Test
Single Best 0.766 (0.030) 0.768 0.754 (0.031) 0.748 0.789 (0.023) 0.804 0.780 (0.032) 0.751
Oracle 0.914 (0.015) 0.911 0.842 (0.025) 0.844 0.917 (0.013) 0.920 0.850 (0.022) 0.860
Min 0.771 (0.020) 0.765 0.746 (0.027) 0.761 0.792 (0.021) 0.793 0.760 (0.030) 0.764
Max 0.760 (0.023) 0.765 0.742 (0.030) 0.731 0.779 (0.021) 0.779 0.757 (0.030) 0.741
Median 0.773 (0.020) 0.766 0.759 (0.027) 0.766 0.789 (0.029) 0.786 0.768 (0.029) 0.761
Mean 0.777 (0.020) 0.772 0.760 (0.024) 0.744 0.794 (0.019) 0.793 0.780 (0.028) 0.781
Majority 0.683 (0.023) 0.660 0.759 (0.027) 0.738 0.697 (0.027) 0.683 0.768 (0.029) 0.761
QDA 0.771 (0.020) 0.763 0.755 (0.031) 0.738 0.790 (0.022) 0.794 0.769 (0.027) 0.764
Logistic Regression 0.778 (0.021) 0.774 0.762 (0.028) 0.744 0.798 (0.020) 0.805 0.781 (0.030) 0.771
Decision Trees 0.718 (0.044) 0.741 0.748 (0.032) 0.757 0.722 (0.033) 0.678 0.777 (0.032) 0.757
Naı ¨ve Bayes 0.732 (0.027) 0.740 0.759 (0.027) 0.738 0.752 (0.028) 0.753 0.768 (0.029) 0.761
Decision Templates 0.777 (0.021) 0.774 0.755 (0.027) 0.754 0.796 (0.019) 0.797 0.766 (0.026) 0.767
Dempster-Shafer 0.777 (0.021) 0.772 0.755 (0.024) 0.754 0.796 (0.019) 0.796 0.767 (0.026) 0.764
Clustering 0.775 (0.019) 0.773 0.758 (0.029) 0.741 0.797 (0.018) 0.800 0.783 (0.028) 0.784
Local Accuracy 0.777 (0.020) 0.771 0.761 (0.025) 0.741 0.795 (0.019) 0.791 0.781 (0.029) 0.777
Feature 0.750 (0.026) 0.747 0.745 (0.029) 0.751 0.786 (0.021) 0.779 0.780 (0.029) 0.767
The table summarizes the results achieved by the different combination approaches on the training set (10-fold cross validation; standard deviation in brackets) and the
test set. The reference methods are Single Best and Oracle, the non-trainable combiners are named according to their function, the meta-classifiers according to the
statistical learning methods. Decision Templates, Dampster-Shafer, Clustering and Local Accuracy are the methods described in detail in the Methods section. Feature is
the combination on the feature level.
doi:10.1371/journal.pone.0003470.t003
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learns faster (gives more reliable predictions with fewer training
data) than the individual prediction systems. Moreover, the curves
show that the combined performance is not dominated by the
single best approach as the results on the full training set might
suggest. Furthermore, the learning curve for the combination on
the feature level indicates that more training data is needed to
achieve full performance. In general, combining the three
individual approaches leads to a reduction of the standard
deviation for almost all combination methods. This suggests a
more robust behavior of the combined system.
In the cases of failing regimens, all three classifiers very
frequently agree upon the wrong label, precisely in 350 of 900
(39%) failing regimens in the training data using the minimal
feature set. There are two possible scenarios why the VL drop
below 500 copies per ml did not take place during the observed
time interval despite the concordant prediction of success by all the
three engines:
1. Resistance against one or more antiretroviral agents is not
visible in the available baseline genotype but stored in the viral
population and rapidly selected, which would lead to an initial
decrease in VL shortly after therapy switch, and a subsequent
rapid increase before the target time frame.
2. The patient/virus is heavily pretreated and therefore it takes
longer to respond to the changed regimen, or the patient is not
completely adherent to the regimen, both cases lead to a
delayed reduction in VL after the observed time frame.
Figure 1. Improvement in AUC of combination methods compared to the single best and single worst classifiers. The figure displays
the improvement in AUC of all combination methods over the single best (blue bars) and single worst (red bars) classifiers on the training set (upper
panel) and the test set (lower panel). Significance of the improvement on the training set was computed with a one-sided paired Wilcoxon test.
Solidly colored bars indicate significant (at a 0.05 p-value threshold) improvements, as opposed to lightly shaded bars for insignificant improvements.
On the test set no p-values could be computed.
doi:10.1371/journal.pone.0003470.g001
Figure 2. Learning curves for the individual classifiers, the
mean combiner, and the combination on feature level. The
figure shows the development of the mean AUC on the test set
depending on the amount of available training data for the individual
classifiers, the mean combiner, and the combination on the feature
level using the minimal feature set. Error bars indicate the standard
deviation on 10 repetitions.
doi:10.1371/journal.pone.0003470.g002
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PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3470Figure3shows the distributionofpredicted successprovided by the
mean combiner using the minimal feature set. There is a clear peak
around 0.8 for instances labeled as success whereas the predictions for
the failing cases seem to be uniformly distributed. Interestingly, the
distribution of the failing cases with a VL below 500 copies per ml
resembles more the distribution for success than for failure.
The approach to predicting the change in VL exhibited
moderate performance. In general, the task of predicting change
in VL is harder, since many host factors, which are not available to
the prediction engines, contribute to the effective change in
individual patients. However, guidelines for treating HIV patients
recommend a complete suppression of the virus below the limit of
detection [25]. Thus, dichotomizing the outcome and instead
solving the classification task is an adequate solution, since
classifiers can be used for computing the probability of achieving
complete suppression.
Conclusion
The use of the maximal feature set consistently outperformed the
minimal feature set in the combined system. Among the studied
combination approaches the logistic regression performed best,
although not significantly better than the mean of the individual
classifications. The mean is a simple and effective combination
method for this scenario. Variations in the size of the training set
showed that a system combining the individual classifiers by the
mean achieves better performance with fewer training samples than
the individual classifiers themselves or a logistic regression using all
the features of the individual classifiers. This and the consistent
reduction of the standard deviation of the performance measures
lead to the conclusion that the mean combiner is more robust than
the individual classifiers, although the performance is not always
significantly improved. Moreover, the mean is a combination
strategy that is easily explainable to the end-users of the system.
In this study we discovered ambiguous failures. These therapies are
classified as failure but have a VL measurement below 500 copies per
ml. Although these instances did neither significantly influence the
learning of the individual classifiers nor the learning of the
combination method, they lead to an underestimation of the
performance. This suggests that clinically relevant adjustments of
the definition of successand failurecan resultin increased accuracy of
the combined engine. Comparative studies aiming at evaluating
EuResist vs. state-of-the-art systems and expert opinion are under
way.
The combined EuResist prediction system is freely available
online at http://engine.euresist.org.
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Table 4. Results on the (un)cleaned test set when individual classifiers are trained on the (un)cleaned training set.
Engine minimal features set maximal feature set
ambiguous instances removed from ambiguous instances removed from
none only train only test both none only train only test both
GD 0.744 0.738 0.784 0.786 0.760 0.747 0.808 0.806
ME 0.745 0.739 0.770 0.771 0.742 0.757 0.808 0.810
EV 0.768 0.776 0.811 0.824 0.804 0.812 0.846 0.855
Mean 0.772 0.767 0.812 0.814 0.793 0.791 0.849 0.849
Feature 0.747 0.754 0.797 0.808 0.779 0.787 0.832 0.842
The table summarizes the results, measured in AUC for the individual classifiers, the mean combiner, and the combination of feature level when retrained on the
(un)cleaned training set and tested on the (un)cleaned test set. Cleaned refers to the removal of ambiguous failing instances.
doi:10.1371/journal.pone.0003470.t004
Table 5. AUC for the combined engines on training set and
test set with the ambiguous cases removed from test set and
training set or test set only.
Method minimal feature set maximal feature set
Train Test Train Test
removed from test only
Single Best 0.809 (0.021) 0.811 0.839 (0.017) 0.847
Oracle 0.935 (0.012) 0.936 0.945 (0.014) 0.950
Min 0.817 (0.019) 0.807 0.847 (0.022) 0.848
Max 0.807 (0.024) 0.810 0.832 (0.018) 0.824
Median 0.820 (0.020) 0.810 0.844 (0.021) 0.835
Mean 0.823 (0.019) 0.816 0.850 (0.019) 0.847
Logistic Regression 0.824 (0.019) 0.816 0.852 (0.017) 0.856
Decision Templates 0.823 (0.018) 0.818 0.851 (0.019) 0.850
Clustering 0.822 (0.020) 0.808 0.852 (0.017) 0.850
Local Accuracy 0.823 (0.019) 0.813 0.850 (0.019) 0.844
removed from train and test
Logistic Regression 0.825 (0.019) 0.816 0.852 (0.017) 0.856
Decision Templates 0.823 (0.018) 0.818 0.851 (0.019) 0.850
Clustering 0.822 (0.021) 0.796 0.852 (0.017) 0.844
Local Accuracy 0.823 (0.019) 0.813 0.850 (0.019) 0.843
The table displays the results, measured in AUC, on training set (10-fold cross
validation; standard deviation in brackets) and test set for a selection of
combination approaches when trained on the (un)cleaned training set. For
computation of the AUC the ambiguous cases were always removed.
doi:10.1371/journal.pone.0003470.t005
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Figure 3. Distribution of predicted success probabilities. Distribution of the predicted success for all successful therapies (blue solid), all
failing therapies (red solid), failing therapies with at least one VL measure below 500 during the regimen (red dashed), and failing therapies with allV L
measures above 500 (red dotted) of the mean combiner using the minimal feature set.
doi:10.1371/journal.pone.0003470.g003
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